San Francisco, US-based health care technology company, InsightRX, has created InsightRX Nova, a cloud-based precision dosing application enabling clinicians to individualize medication dosing regimens ‘at the bedside.’
HealthX Ventures led the company’s Series A funding, with participation from Rock Health, OSF Healthcare, Leawood Venture Capital, Premier, and earlier investor GreatPoint Ventures.
The funding round closed with the technology company raising $10m (€9.09m), bringing its total funding since its founding in 2015 to more than $13m.
The company’s technology platform processes real-world clinical data using artificial intelligence (AI) to guide treatment decisions based on each patient's pharmacological profile.
To date, InsightRX Nova is applicable in more than 100 therapeutic areas, including oncology and infectious diseases.
The platform is currently adopted by health care centers to improve the effectiveness of commercially available drugs, as well as by biopharmaceutical developers, enabling them to incorporate precision dosing early in the drug development process.
Sirj Goswami, the company’s co-founder and CEO, told us that incorporating precision dosing technology as part of a clinical trial “minimizes the impact of pharmacological variation on trial endpoints.”
Furthermore, the InsightRX analytics and machine learning capabilities enable researchers “to quickly learn about patient drug response profiles by monitoring and predicting clinical outcomes and adverse drug events,” Goswami added.
Under its partnerships with drug developers, InsightRX works to develop “drug-specific companion applications” for use in clinical trials, similar to the precision dosing modules that the company already offer to providers, according to the company’s CEO.
“Depending on our pharma partner’s needs, we may perform some additional customization of a module to better match the patient population for which the trial is recruiting,” Goswami explained.
The company’s ultimate goal is to include the ‘companion application’ as part of the drug label, accelerating the adoption of precision dosing on a global scale.
According to Goswami, the first stepis to implement precision dosing within clinical trials to “reduce adverse events and increase the chance that clinical targets are reached, thus increasing the overall chance that a trial will succeed.”
In anticipation of a trial succeeding where individualized dosing is critical to achieving clinical endpoints, “we are working with regulators and pharma partners to understand the scope of what will eventually be required to include model-informed precision dosing in the drug label,” Goswami concluded.